BioSpace News Archive

Alumis Inc. today announced that the first patient has been dosed in Stride, a Phase 2 clinical trial of ESK-001 for the treatment of patients with moderate to severe plaque psoriasis. ESK-001 is a highly selective and potentially best in class allosteric tyrosine kinase 2 (TYK2) inhibitor.

Ironshore Therapeutics Inc. today announced the appointments of Lewis Warrington as Chief Medical Officer, Nelson F. Isabel as Chief Financial Officer, Nilay Patel as Chief Legal Officer and Tim Branz as Chief Information Officer.

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO ® Admixture to 96 Hours Following Reconstitution.

Gandeeva Therapeutics, Inc. , a precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to advance drug discovery, announced today the appointment of Matthew Lucas, Ph.D., as Chief Scientific Officer and David Poon, Ph.D., as Chief Business Officer to the leadership team.

Sight Sciences, Inc., announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery during this year’s annual AAO convention at McCormick Place in Chicago, IL.

Citius Pharmaceuticals, Inc. today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Ichnos Sciences Inc. today announced dosing of the first patient in the Phase 1/2 dose escalation and expansion study of ISB 1442, a CD38 x CD47 biparatopic bispecific antibody for the treatment of relapsed/refractory multiple myeloma.

HeartBeam, Inc. announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the United States Patent and Trademark Office.

ACT Laboratories, Inc. (“ACT Labs”), a leading lab testing company in the legal cannabis and hemp markets, today announced an agreement to acquire CDX Analytics, LLC (“CDX”) of Massachusetts to continue its geographic expansion and extend its scientific leadership.

iuvo BioScience today announced it has signed a definitive agreement to be acquired by Ampersand Capital Partners.